EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study

Anne-Geneviève Marcelin, Cathia Soulie iD, Marc Wirden iD, Guillaume Barriere iD, François Durand, Charlotte Charpentier, Diane Descamps, Vincent Calvez

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae377 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Anne-Geneviève Marcelin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Pa…. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Viral, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Gilead Sciences Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens.

Objectives

The Virostar-1 study objective is to analyse the emergence of resistance-associated mutations (RAMs) over 3 years with DTG-based 2DRs and DTG- or bictegravir (BIC)-based 3DRs in people living with HIV (PLWH) experiencing a VF (FL or SL).

Methods

Retrospective analysis of genotypic resistance detected at the time of a FL or SL VF with BIC/FTC/TAF, DTG/ABC/3TC, DTG/3TC and DTG/RPV between 2019 and 2022 was conducted from a French multicentre database. VF was defined as two consecutive HIV-1 plasma viral loads > 50 c/mL. Sanger assays were performed at VF within standard clinical care. Resistance mutations were reported using the ANRS algorithm. Selection biases prevent group comparisons.

Results

During the period, N = 5986 PLWH were followed either in FL or SL. The VF rate was overall low: BIC/FTC/TAF, 6.8%; DTG/ABC/3TC, 7.5%; DTG/3TC, 5.1%; and DTG/RPV, 2.1%. Some emergent InSTI or NRTI RAMs were detected with BIC/FTC/TAF 4%, DTG/ABC/3TC 8.5%, DTG/3TC 18% and 39% emergent NNRTI RAMs with DTG/RPV. However, a complete absence of dual resistance against NRTIs and InSTIs was observed.

Conclusions

We detected rare emergent InSTI RAMs and few emergent NRTI RAMs in PLWH failing DTG- or BIC-based regimens in FL or SL. The observed rates of emergent RAMs at VF were 4% with BIC/FTC/TAF, 8.5% with DTG/ABC/3TC, 18% with DTG/3TC and 39% with DTG/RPV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Drug Resistance, ViralMutationTreatment FailureHumansRetrospective StudiesMaleFemaleViral LoadHIV Integrase InhibitorsAdultAnti-HIV AgentsMiddle AgedHeterocyclic Compounds, 3-RingGenotypeDrug Therapy, CombinationAmidesPiperazinesPyridones

Substanzen

HIV Integrase InhibitorsAnti-HIV AgentsbictegravirHeterocyclic Compounds, 3-RingAmidesPiperazinesPyridones

Autor:innen und Institutionen

  • Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France.
  • Medical Department, Gilead Sciences, S.A.S., Boulogne-Billancourt, France.
  • Université Paris Cité, INSERM, IAME, AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, Paris, France.

ORCID-Profile: Cathia Soulie, Marc Wirden, Guillaume Barriere

Förderung

  • Gilead Sciences
  • Gilead Sciences Inc

Zitieren

APA

Marcelin, A. G., Soulie, C., Wirden, M., Barriere, G., Durand, F., Charpentier, C., Descamps, D., & Calvez, V. (2025). Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae377

Vancouver

Marcelin AG, Soulie C, Wirden M, Barriere G, Durand F, Charpentier C, et al. Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae377

BibTeX
@article{Marcelin2025,
  author = {Marcelin, Anne-Geneviève and Soulie, Cathia and Wirden, Marc and Barriere, Guillaume and Durand, François and Charpentier, Charlotte and Descamps, Diane and Calvez, Vincent},
  title = {Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae377}
}
Kostenlos starten →